Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FOLD – Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.
FOLD
$5.73
Name : Amicus Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,764,444,672.00
EPSttm : -0.09
finviz dynamic chart for FOLD
Amicus Therapeutics, Inc.
$5.73
3.37%
$0.2

Float Short %

7.03

Margin Of Safety %

53

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.18

EPS Last/This Y

0.51

EPS This/Next Y

0.35

Price

5.73

Target Price

16.2

Analyst Recom

1.36

Performance Q

-32.03

Relative Volume

1.09

Beta

0.52

Ticker: FOLD




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02FOLD6.160.370.0115432
2025-06-03FOLD6.260.370.0015357
2025-06-04FOLD6.090.378.4015358
2025-06-05FOLD5.940.370.2915412
2025-06-06FOLD6.150.361.5415587
2025-06-09FOLD6.030.370.0315833
2025-06-10FOLD6.120.370.0015988
2025-06-11FOLD6.140.370.0016003
2025-06-12FOLD6.180.370.2016016
2025-06-13FOLD6.030.370.0016043
2025-06-16FOLD6.040.370.0816033
2025-06-17FOLD5.80.342.2115716
2025-06-18FOLD5.720.360.0016148
2025-06-20FOLD5.650.365.0016146
2025-06-23FOLD5.70.310.1414389
2025-06-24FOLD5.70.300.0814470
2025-06-25FOLD5.660.260.2014025
2025-06-26FOLD5.680.263.8814036
2025-06-27FOLD5.930.260.5414068
2025-06-30FOLD5.730.260.0014101
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02FOLD6.15-60.00.10.33
2025-06-03FOLD6.26-60.00.10.33
2025-06-04FOLD6.09-60.0-1.70.33
2025-06-05FOLD5.96-60.0-1.50.33
2025-06-06FOLD6.15-60.00.70.33
2025-06-09FOLD6.03-60.0-1.40.33
2025-06-10FOLD6.12-60.00.00.33
2025-06-11FOLD6.14-60.0-0.30.33
2025-06-12FOLD6.17-60.0-0.40.33
2025-06-13FOLD6.03-60.0-1.50.33
2025-06-16FOLD6.05-60.0-0.50.33
2025-06-17FOLD5.79-60.0-2.30.33
2025-06-18FOLD5.73-60.0-1.10.33
2025-06-20FOLD5.64-60.0-1.20.33
2025-06-23FOLD5.70-60.0-0.10.33
2025-06-24FOLD5.70-64.2-0.60.33
2025-06-25FOLD5.66-64.2-0.90.33
2025-06-26FOLD5.69-64.2-0.40.33
2025-06-27FOLD5.92-64.21.10.33
2025-06-30FOLD5.73-64.2-1.90.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02FOLD-0.072.656.79
2025-06-03FOLD-0.072.656.79
2025-06-04FOLD-0.002.656.79
2025-06-05FOLD-0.002.656.79
2025-06-06FOLD-0.002.656.79
2025-06-09FOLD-0.002.706.79
2025-06-10FOLD-0.002.706.79
2025-06-11FOLD-0.002.706.66
2025-06-12FOLD-0.002.706.66
2025-06-13FOLD-0.002.706.66
2025-06-16FOLD-0.003.026.66
2025-06-18FOLD-0.003.026.66
2025-06-20FOLD-0.003.026.66
2025-06-23FOLD-0.003.046.66
2025-06-24FOLD-0.003.046.66
2025-06-25FOLD-0.003.046.66
2025-06-26FOLD-0.003.047.03
2025-06-27FOLD-0.003.047.03
2025-06-30FOLD-0.002.927.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

0.02

Avg. EPS Est. Next Quarter

0.11

Insider Transactions

Institutional Transactions

2.92

Beta

0.52

Average Sales Estimate Current Quarter

146

Average Sales Estimate Next Quarter

164

Fair Value

8.75

Quality Score

58

Growth Score

53

Sentiment Score

78

Actual DrawDown %

77.4

Max Drawdown 5-Year %

-77.3

Target Price

16.2

P/E

Forward P/E

22.18

PEG

P/S

3.25

P/B

9.12

P/Free Cash Flow

1095.93

EPS

-0.09

Average EPS Est. Cur. Y​

0.33

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-5.41

Relative Volume

1.09

Return on Equity vs Sector %

-39

Return on Equity vs Industry %

-19.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-1.9
Amicus Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 499
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today
news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance
stock history FOLD – Amicus Therapeutics, Inc. invest stock market
stock prices FOLD premarket after hours
ticker FOLD fair value insiders trading